Pharma
- What applies
- Medicinal product trials follow ICH E6(R3) and the Clinical Trials Regulation (EU) 536/2014.
How do sponsors safeguard the data quality and GCP compliance of their clinical trial through effective clinical monitoring?
We run clinical monitoring under ICH E6, also with interim CRAs: source data verification, protocol adherence, informed consent review and escalation of deviations. Without a documented risk assessment, reduced monitoring looks in an inspection like a failure to oversee the trial, not like an efficient approach.
Overview
What monitoring risks arise in clinical trials?
Monitoring across drug and medical device trials · ICH E6(R3) (GCP), EU 536/2014 (CTR), EU 2017/745 (MDR), ISO 14155:2020
Last updated: October 6, 2026
Inadequate clinical monitoring is one of the most common causes of findings in GCP inspections. Under ICH E6, responsibility for oversight remains with the sponsor, even when tasks are delegated to a CRO or to individual CRAs.
- Protocol deviations accumulate undetected when monitoring visits are too infrequent or carried out without risk-based prioritization. A monitoring plan with no link to the critical data points of the trial fails to achieve the purpose of oversight under ICH E6(R3).
- Informed consent documentation is incomplete or not compliant. Under ICH E6, the protection of trial participants and the usability of the data depend directly on consent that has been properly obtained and documented.
- Source data verification is incomplete, or the case report forms diverge from the source data. If entries cannot be substantiated against the source documents, the data integrity of the trial cannot be demonstrated.
- Reduced monitoring is introduced without documenting the underlying risk analysis. Risk-based monitoring is permitted under ICH E6(R3), but only on the basis of a traceable, documented risk assessment. Without it, it looks like a failure to oversee the trial.
Industries
What this means in your industry
Biotech
- What applies
- As in pharma: ICH E6(R3) and the Clinical Trials Regulation (EU) 536/2014.
MedTech
- What applies
- Clinical investigations of medical devices follow the MDR (EU) 2017/745 and ISO 14155:2020.
IVD
- What applies
- Performance studies for in vitro diagnostics follow the IVDR (EU) 2017/746.
Services
How we support you
On-site monitoring & source data verification
Full monitoring visits at the investigational sites in line with ICH E6: informed consent review, source data verification against the source documents, tracking of protocol deviations, training of site staff and escalation of open items. Deliverable: written monitoring visit reports to ICH E6 standard.
Remote & central monitoring
A combination of remote monitoring and central data oversight to identify anomalous patterns across sites. Prioritization of the critical data points without full source data verification at every site. Deliverable: documented central monitoring analyses and remote reports.
Risk-based monitoring & monitoring plan
Building a risk-based monitoring approach in line with ICH E6(R3): identification of critical data and processes, definition of visit frequency and monitoring mix per risk level. Deliverable: monitoring plan with a documented risk assessment.
CRA interim & team extension
Deployment of Entourage CRAs into ongoing trial teams: to bridge vacancies, for individual sites, or as additional capacity during high-recruitment phases. Deliverable: ready-to-deploy CRAs with a documented handover into the monitoring plan and TMF.
How we work together
What it comes down to
Effective clinical monitoring does not begin with the first site visit, but with the risk assessment. Under ICH E6(R3), the entire monitoring approach is derived from the question of which data and processes in a trial are critical. Only from this do visit frequency and the mix of on-site monitoring, remote monitoring and central data oversight follow.
A blanket visit frequency ties up resources at low-risk sites while the anomalous ones go unnoticed. This is the most common reason why protocol deviations accumulate undetected.
The real difficulty here is rarely the individual deviation, but its traceability: reduced source data verification is permitted, but only with a documented risk analysis, and every finding must be traceable from visit report through follow-up and closure all the way into the Trial Master File.
Our CRAs anchor the risk assessment in the monitoring plan before the first participant is enrolled, and keep sponsor oversight under ICH E6 consistently documented, even when monitoring tasks are delegated to a CRO and responsibility remains with the sponsor.
Our approach
Our approach
Step
Result
01
Risk assessment & monitoring plan
Identified critical data and processes, the resulting monitoring mix and visit frequency, documented in the monitoring plan in line with ICH E6(R3).
02
Site initiation
Trained site staff, reviewed trial documents, a documented initiation visit before enrollment of the first participant.
03
Ongoing monitoring
On-site and remote visits performed with source data verification, informed consent review and tracking of protocol deviations.
04
Escalation & follow-up
Assessed and tracked findings, escalated critical deviations, closed action items per site.
05
Close-out
Close-out visit performed, complete and inspection-ready filing of the monitoring-relevant documents in the TMF.
Common pitfalls
Where projects commonly fail
Monitoring frequency is set uniformly across all sites.
Without risk-based prioritization in line with ICH E6(R3), anomalous or high-recruitment sites receive too little attention, while low-risk sites tie up resources.
Protocol deviations are recorded in the visit reports, but not assessed.
Recurring deviations of the same type without root cause analysis demonstrate to the inspector a systemic problem in quality management under ICH E6, not just isolated errors at a single site.
Sponsor oversight of delegated monitoring exists only on paper.
Under ICH E6, the sponsor remains responsible for oversight, even when monitoring is fully delegated to a CRO. Without documented reviews of the monitoring reports and escalation paths, this is a standard finding in GCP inspections.
Monitoring findings are closed, but not filed traceably in the TMF.
If visit reports, follow-up and closure of the action items cannot be reconstructed throughout the trial, there is no evidence that oversight actually had any effect.
Product Development & Regulatory Strategy
Do any of these pitfalls apply to you?
In a first call we assess your situation and say what needs clarifying first in your case. Without obligation, reply usually within one working day.
FAQ
Frequently asked questions
A CRA oversees the clinical investigational sites on behalf of the sponsor in line with ICH E6. Core tasks include reviewing the trial documents, source data verification, checking protocol adherence, training site staff and communicating with the site. The CRA is the link between sponsor and site and documents oversight in monitoring visit reports.
Risk-based monitoring under ICH E6(R3) prioritizes oversight resources on the basis of a documented risk assessment: which data points are critical, which sites show anomalies. It combines on-site visits with remote monitoring and central data oversight. The prerequisite is a traceably documented risk analysis; without it, reduced monitoring cannot be substantiated.
The frequency is trial- and risk-based and is defined in the monitoring plan in line with ICH E6. An initiation visit before enrollment of the first participant and a close-out visit are standard; the frequency in between depends on the recruitment volume and risk level of the respective site. A uniform frequency for all sites contradicts the risk-based approach.
Clinical monitoring is the operational oversight at the sites, such as source data verification and checking protocol adherence. Clinical compliance is the overarching framework: ensuring that all regulatory requirements under ICH E6, EU 536/2014 or EU 2017/745 are met, across monitoring, audits, TMF management and safety reporting.
Yes. Clinical investigations of medical devices are governed by EU 2017/745 (MDR) and ISO 14155:2020, and performance studies for in vitro diagnostics by EU 2017/746 (IVDR). Monitoring follows the same fundamental principles as for drug trials, but the reports and focus are tailored to the respective type of investigation.
Our CRAs work across Europe and have experience with international trial settings. Drug trials in the EU follow EU 536/2014; for trials outside the EU, we coordinate monitoring with local partners so that sponsor oversight under ICH E6 remains consistently documented.
Sources
- ICH E6(R3), Good Clinical Practice (primary text, Step 4 of 6 January 2025)
- Regulation (EU) 536/2014 (Clinical Trials Regulation), primary text
- Regulation (EU) 2017/745 (MDR), primary text, clinical investigations
- Regulation (EU) 2017/746 (IVDR), primary text, performance studies
- EN ISO 14155:2020 with A11:2024, Clinical investigation of medical devices for human subjects (harmonized under the MDR, Implementing Decision (EU) 2026/193; the new ISO edition 14155:2026 is not yet harmonized)
Image notice: The images on this page were generated using artificial intelligence. They do not depict real people, places, or events.
Life Science Journal
Regulatory updates, straight to your inbox.
New requirements, authority decisions and practice notes. Once a month, unsubscribe any time.
Projects from this industry
What we have worked on in this industry
Related insights
All insights →Regulations & standards considered
- ICH E6(R3) (Good Clinical Practice)
- EU 536/2014 (Clinical Trials Regulation, CTR)
- EU 2017/745 (MDR)
- EU 2017/746 (IVDR)
- EN ISO 14155:2020 with A11:2024 (Clinical investigation of medical devices; the version harmonized under the MDR, the new ISO edition 14155:2026 is not yet listed there)
Related topics
Clinical Compliance →
The overarching GCP framework of audits, TMF management and inspection readiness
Good Clinical Practice (GCP) →
The foundations under ICH E6 on which monitoring builds
Clinical Project Management →
Operational trial management into which monitoring is embedded
CRO Support →
Steering and oversight of delegated monitoring services
Have a concrete project?
Briefly outline your situation. We'll respond with an initial assessment, usually within one business day.
Prefer direct? +49 89 4161170-0
info@theentourage.de
- Reply usually within one working day
- 4 offices: DE · CH · IT · US
- 100% life sciences